Roche\'s Tecentriq chalks up another FDA approval this time in firstline extensivestage small cell lung cancer

Roche's Tecentriq chalks up another FDA approval, this time in first-line extensive-stage small cell lung cancer

06:38 EDT 20 Mar 2019 | Pharmafile

Roche has secured another US approval for its immunotherapy Tecentriq (atezolizumab), as the FDA reveals its approval of the drug in combination with chemotherapy (carboplatin and etoposide) in the initial treatment of extensive-stage small cell lung cancer (ES-SCLC).

The decision makes the combo the first and only such treatment available in this indication, and the first new treatment for ES-SCLC in more than two decades.

Roche\'s Tecentriq chalks up another FDA approval this time in firstline extensivestage small cell lung cancer

Roche's Tecentriq chalks up another FDA approval, this time in first-line extensive-stage small cell lung cancer

Roche has secured another US approval for its immunotherapy Tecentriq (atezolizumab), as the FDA reveals its approval of the drug in combination with chemotherapy (carboplatin and etoposide) in the initial treatment of extensive-stage small cell lung cancer (ES-SCLC).

More From BioPortfolio on "Roche's Tecentriq chalks up another FDA approval, this time in first-line extensive-stage small cell lung cancer"